Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by BMJ Technology Assessment Group:

  • Edwards SJ, Barton S, Nherera L, Trevor N, Hamilton V. Ivabradine for the treatment of chronic heart failure: A Single Technology Appraisal. BMJ-TAG, London, 2012.

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Servier Laboratories

II Professional/specialist and patient/carer groups:

  • South Asian Health Foundation

  • British Association for Nursing in Cardiac Care

  • British Cardiovascular Society

  • British Heart Foundation

  • British Society for Heart Failure

  • Royal College of Nursing

  • Royal College of Physicians

III Other consultees:

  • Department of Health

  • NHS Devon

  • Welsh Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Health Care Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • Pfizer

  • National Clinical Guidelines Centre

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on Ivabradine for the treatment of chronic heart failure by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Martin Cowie, Professor of Cardiology, nominated by British Cardiovascular Society – clinical specialist

  • Dr Suzanna Hardman, Consultant Cardiologist, Nominated by Royal College of Physicians – clinical specialist

  • Dr Simon Williams, nominated by Servier Laboratories Ltd – clinical specialist

  • Liz Clark, nominated by NHS Devon and Heart Care Partnership – patient expert

D The following individuals were nominated as NHS Commissioning experts by the selected NHS Trust allocated to this appraisal. They gave their expert/NHS commissioning personal view on Ivabradine for the treatment of chronic heart failure by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Tina Teague, Head of Locality Commissioning, selected by NHS Devon – NHS Commissioning expert

E Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Servier Laboratories

  • National Institute for Health and Care Excellence (NICE)